Fermented zinc improves bioavailability

Glycoprotein matrix zinc exhibits improved absorption: a randomized crossover trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN67008850

Enrollment

Registered

2024-02-12

Start date

2023-10-05

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy subjects Not Applicable

Interventions

Following baseline sampling, participants ingested their respective supplements with 350 mL of cold water. Blood samples will be taken at 30-, 60-, 90-, 120-, 180-, 240-, 300-, 360-, 420- and 480-minu

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Healthy adults 2. A normal body weight (body mass index (BMI) of 19–24.99 kg/m2) 3. Recreationally active (according to American College of Sports Medicine Guidelines)

Exclusion criteria

Exclusion criteria: 1. Currently being treated for or diagnosed with a gastrointestinal, cardiac, respiratory, circulatory, musculoskeletal, metabolic, immune, autoimmune, psychiatric, hematological, neurological or endocrinological disorder 2. Participants determined to not be weight stable defined as measured body mass deviating by 2% or more 3. Participants not willing to abstain from alcohol, nicotine, and caffeine for 12 hours before each visit

Design outcomes

Primary

Measure	Time frame
The primary outcome measure in this study is plasma zinc levels measured using inductively coupled plasma/mass spectrometry (ICP/MS) at baseline, and 30-, 60-, 90-, 120-, 180-, 240-, 300-, 360-, 420- and 480-minutes post-ingestion as mcg/dL. The zinc concentrations are used to calculate: 1. Incremental area under the concentration versus time curve (iAUC) as mcg/dL * 480 minutes 2. Maximum observed concentration (Cmax) as mcg/dL 3. The time of maximum observed concentration (Tmax) as minutes	—

Measure

Time frame

The primary outcome measure in this study is plasma zinc levels measured using inductively coupled plasma/mass spectrometry (ICP/MS) at baseline, and 30-, 60-, 90-, 120-, 180-, 240-, 300-, 360-, 420- and 480-minutes post-ingestion as mcg/dL. The zinc concentrations are used to calculate: 1. Incremental area under the concentration versus time curve (iAUC) as mcg/dL * 480 minutes 2. Maximum observed concentration (Cmax) as mcg/dL 3. The time of maximum observed concentration (Tmax) as minutes

—

Secondary

Measure	Time frame
Adverse events measured using the GI Health questionnaire evaluating and ranking stomach ache, abdominal pain or cramps, bloating, subjective impression of rectal gas excretion and nausea side effects on a scale from 0 (no symptoms) to 5 (severe symptoms) before and 480 minutes post-ingestion. In addition, participants will be asked to rank the severity of dizziness, headache, fast or racing heart rate, heart skipping or palpitations, shortness of breath, nervousness, blurred vision, and other unusual or adverse effects on a scale from 0 (none) to 5 (very severe).	—

Measure

Time frame

Adverse events measured using the GI Health questionnaire evaluating and ranking stomach ache, abdominal pain or cramps, bloating, subjective impression of rectal gas excretion and nausea side effects on a scale from 0 (no symptoms) to 5 (severe symptoms) before and 480 minutes post-ingestion. In addition, participants will be asked to rank the severity of dizziness, headache, fast or racing heart rate, heart skipping or palpitations, shortness of breath, nervousness, blurred vision, and other unusual or adverse effects on a scale from 0 (none) to 5 (very severe).

—

Countries

United States of America

Contacts

Public ContactLem Taylor

ltaylor@umhb.edu+1-254-295-4895

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026